142 related articles for article (PubMed ID: 10713698)
1. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors.
Bearss DJ; Subler MA; Hundley JE; Troyer DA; Salinas RA; Windle JJ
Oncogene; 2000 Feb; 19(8):1114-22. PubMed ID: 10713698
[TBL] [Abstract][Full Text] [Related]
2. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
Barrington RE; Subler MA; Rands E; Omer CA; Miller PJ; Hundley JE; Koester SK; Troyer DA; Bearss DJ; Conner MW; Gibbs JB; Hamilton K; Koblan KS; Mosser SD; O'Neill TJ; Schaber MD; Senderak ET; Windle JJ; Oliff A; Kohl NE
Mol Cell Biol; 1998 Jan; 18(1):85-92. PubMed ID: 9418856
[TBL] [Abstract][Full Text] [Related]
3. p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors.
Petit T; Bearss DJ; Troyer DA; Munoz RM; Windle JJ
Mol Cancer Ther; 2003 Feb; 2(2):165-71. PubMed ID: 12589033
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors.
Hundley JE; Koester SK; Troyer DA; Hilsenbeck SG; Barrington RE; Windle JJ
Cancer Res; 1997 Feb; 57(4):600-3. PubMed ID: 9044833
[TBL] [Abstract][Full Text] [Related]
6. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53.
Hundley JE; Koester SK; Troyer DA; Hilsenbeck SG; Subler MA; Windle JJ
Mol Cell Biol; 1997 Feb; 17(2):723-31. PubMed ID: 9001226
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
[TBL] [Abstract][Full Text] [Related]
8. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
[TBL] [Abstract][Full Text] [Related]
9. Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene.
Mangues R; Seidman I; Pellicer A; Gordon JW
Oncogene; 1990 Oct; 5(10):1491-7. PubMed ID: 2174525
[TBL] [Abstract][Full Text] [Related]
10. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia.
Daphna-Iken D; Shankar DB; Lawshé A; Ornitz DM; Shackleford GM; MacArthur CA
Oncogene; 1998 Nov; 17(21):2711-7. PubMed ID: 9840935
[TBL] [Abstract][Full Text] [Related]
11. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
[TBL] [Abstract][Full Text] [Related]
12. Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion.
Chatterjee G; Rosner A; Han Y; Zelazny ET; Li B; Cardiff RD; Perkins AS
Am J Pathol; 2002 Dec; 161(6):2241-53. PubMed ID: 12466138
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
14. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
15. Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency.
Feng F; Rittling SR
Breast Cancer Res Treat; 2000 Sep; 63(1):71-9. PubMed ID: 11079161
[TBL] [Abstract][Full Text] [Related]
16. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.
Jackson JG; Pant V; Li Q; Chang LL; Quintás-Cardama A; Garza D; Tavana O; Yang P; Manshouri T; Li Y; El-Naggar AK; Lozano G
Cancer Cell; 2012 Jun; 21(6):793-806. PubMed ID: 22698404
[TBL] [Abstract][Full Text] [Related]
17. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype.
Podsypanina K; Li Y; Varmus HE
BMC Med; 2004 Jun; 2():24. PubMed ID: 15198801
[TBL] [Abstract][Full Text] [Related]
18. Structural analysis of the ras transgene in MMTV/v-Ha-ras transgenic mice.
DeWille JW; Farmer SJ
Lab Anim Sci; 1994 Apr; 44(2):131-4. PubMed ID: 8028274
[TBL] [Abstract][Full Text] [Related]
19. In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53.
Hosokawa Y; Papanikolaou A; Cardiff RD; Yoshimoto K; Bernstein M; Wang TC; Schmidt EV; Arnold A
Transgenic Res; 2001 Oct; 10(5):471-8. PubMed ID: 11708657
[TBL] [Abstract][Full Text] [Related]
20. Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function.
Margalit O; Simon AJ; Yakubov E; Puca R; Yosepovich A; Avivi C; Jacob-Hirsch J; Gelernter I; Harmelin A; Barshack I; Rechavi G; D'Orazi G; Givol D; Amariglio N
Int J Cancer; 2012 Aug; 131(4):E562-8. PubMed ID: 21932419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
